Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are searching for regenerative options while living in or traveling to Japan, you may have come across adipose-derived stem cell therapy. Questions about cost and logistics usually come first, but one question tends to be overlooked: what exactly does the cell culture step involve, and why does it matter to you as a patient? This article explains how cultured stem cells are prepared from your own fat tissue, what the process means for timing and planning, and what to ask a doctor before deciding.
The short answer: your own cells are collected, cultured, and then returned
In adipose-derived stem cell therapy, a very small amount of fat tissue is collected from your body under local anesthesia. Mesenchymal stem cells contained in that tissue are then cultured and expanded at a specialized facility. Later, the cultured cells are returned to your body by intravenous infusion. At Grand Green Osaka Umekita Clinic in Osaka, this is offered as an outpatient treatment, so hospitalization is not part of the standard flow.
It is important to be realistic. This is a self-pay (non-insured) treatment, and the effects reported in research vary between individuals and conditions. It is not a replacement for standard medical care, and whether it is suitable for you can only be decided after a consultation with a physician.
Why the culture step matters
A small fat sample contains only a limited number of mesenchymal stem cells. Culturing, also called expansion, is the process of letting those cells multiply under controlled laboratory conditions so that enough of them are available for infusion. Because the cells are grown outside the body, the process takes time, and it is carried out at a processing facility that meets the requirements set under Japanese regulation.
For international patients, this has a practical consequence. The treatment is not completed in a single visit. There is a collection visit, a waiting period while the cells are prepared, and an infusion visit. The exact length of each stage should be confirmed with the clinic, because it depends on the individual plan and the facility. If you are traveling from abroad, you may want to ask how the two visits can be scheduled around your work and travel.
What the research says, and what it does not
Mesenchymal stem cells are somatic stem cells found in fat tissue, bone marrow, and other sources. In addition to their ability to differentiate into fat, bone, and cartilage cells, they have been reported to release anti-inflammatory substances and growth factors that may support the repair of damaged tissue. Research is ongoing worldwide, including studies on joint conditions such as osteoarthritis.
However, results from individual studies should not be generalized. Study designs, cell sources, doses, and patient groups differ, and reported findings do not promise the same outcome for every person. A thoughtful clinic will explain both the potential and the limits of the evidence. If you want to read the primary literature yourself, searching PubMed for terms such as adipose-derived mesenchymal stem cells together with the condition you are interested in is a reasonable place to begin, and a doctor can help you interpret what you find.
How the treatment is regulated in Japan
In Japan, regenerative medicine is provided under the Act on the Safety of Regenerative Medicine. Clinics offering this type of treatment submit a regenerative medicine provision plan, and cell processing is expected to take place at a facility that meets legal requirements. This framework exists to help manage quality and patient protection, but it does not remove the need for you to ask questions.
Useful questions for any clinic include the following:
- Which regenerative medicine plan covers the treatment I am considering, and can I see the explanation of it?
- Where are the cells cultured, and how is quality managed?
- What risks and side effects are possible, including those related to fat collection and infusion?
- Is the treatment suitable for my medical history and current medications?
- What are the total costs, and how many visits are needed?
Because this treatment is outside the national insurance system, costs are paid by the patient. Fees, the number of visits, risks, and eligibility should always be confirmed directly with the physician and the clinic before you agree to anything.
Preparing for a consultation as an international patient
Good preparation makes a consultation more useful. Before you visit or contact the clinic, gather a short summary of your medical history, a list of current medications and supplements, and any recent test results or imaging that relate to your concern. If your records are in another language, bring them anyway, as they can still help the doctor understand your background.
It also helps to write down your questions in advance, especially about timing. Ask how long the culture period is expected to be, whether the infusion date can be adjusted, and what follow-up is recommended after you return home. If you have a chronic condition, mention it openly, since it may affect whether this treatment is appropriate.
Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is convenient for visitors using Shin-Osaka or Osaka Station. The clinic provides an information page for foreign patients, and you can use it to learn how to make an inquiry in your language. Contacting the clinic early gives you time to ask questions without feeling rushed.
Key points to remember
- Adipose-derived stem cell therapy uses your own cells, which are collected from a small amount of fat, cultured, and returned by infusion.
- The culture step takes time, so plan for more than one visit and ask about the schedule.
- Research is ongoing and results differ between individuals, so no outcome can be promised.
- It is a self-pay treatment provided under Japan’s regenerative medicine law, and it does not replace standard care.
- Costs, risks, side effects, and suitability should be confirmed with a doctor during a consultation.
If you are considering this treatment, the most helpful next step is a conversation with a physician who can review your situation and answer your questions in detail. Take your time, compare information carefully, and make the decision that fits your own health needs.
- 1ConsultationDoctor reviews your situation
- 2Fat collectionLocal anesthesia, outpatient
- 3Cell cultureCells expanded at a facility
- 4IV infusionCells returned to your body
This figure is a conceptual summary of the article content
References
- PubMed: Derivation of therapeutic lung spheroid cells from minimally invasive transbronchial pulmonary biopsies. (2017)
- PubMed: Excess Integrins Cause Lung Entrapment of Mesenchymal Stem Cells. (2015)
- PubMed: Ex vivo expansion and in vivo infusion of bone marrow-derived Flk-1+CD31-CD34- mesenchymal stem cells: feasibility and safety from monkey to human. (2006)
- PubMed: Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. (2013)
- PubMed: Identification of a discrete population of human bone marrow-derived mesenchymal cells exhibiting properties of uncommitted progenitors. (2001)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- PMC: Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial. (2026)
- PMC: Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells. (2022)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.